Skip to main content

Table 4 Antibiotic sensitivity of infants with ESBL-positive and ESBL-negative Escherichia coli invasive infection [% (n/N)]

From: Epidemiology and antimicrobial susceptibility of invasive Escherichia coli infection in neonates from 2012 to 2019 in Xiamen, China

Antibiotic ESBL positive group (n = 35) ESBL negative group (n = 87) χ2 values P
β-lactams Ampicillin 2.86 (1/35) 36.78 (32/87) 14.557 0.000
Piperacillin 8.57 (3/35) 35.63 (31/87) 9.092 0.003
Cefazolin 11.43 (4/35) 82.76 (72/87) 54.066 0.000
Ceftazidime 80.00 (28/35) 98.85 (86/87) 11.561 0.001
Cefotaxime 37.14 (13/35) 97.70 (85/87) 57.924 0.000
Cefepime 34.29 (12/35) 98.85 (86/87) 65.842 0.000
Compound preparations of β-lactam inhibitors Amoxicillin/clavulanic acid 57.14 (20/35) 91.95 (80/87) 20.463 0.000
Ampicillin/sulbactam 40.00 (14/35) 57.47 (50/87) 3.055 0.080
Cefoperazone/sulbactam 97.14 (34/35) 100.00 (87/87) 0.287a
Piperacillin/tazobactam 94.29 (33/35) 100.00 (87/87) 0.081a
Carbapenems Imipenem 100.00 (35/35) 100.00 (87/87)
Meropenem 100.00 (35/35) 100.00 (87/87)
Quinolones Levofloxacin 54.29 (19/35) 73.56 (64/87) 4.265 0.039
Ciprofloxacin 48.57 (17/35) 70.11 (61/87) 5.024 0.025
Aminoglycosides Gentamicin 60.00 (21/35) 89.66 (78/87) 14.348 0.000
Amikacin 100.00 (35/35) 100.00 (87/87)
Sulfonamides Compound sulfamethoxazole 28.57 (10/35) 63.22 (55/87) 12.036 0.001
Other antibiotics Aztreonam 65.71 (23/35) 98.85 (86/87) 25.411 0.000
  1. ESBL extended spectrum β-lactamase
  2. aFisher’s exact test